China Issues Revised Good Clinical Practice Guidelines for Drug Clinical Trials

China’s National Medical Products Administration (NMPA), together with the National Health Commission, the State Administration of Traditional Chinese Medicine, and the National Bureau of Disease Control and Prevention, has announced a revised version of the Good Clinical Practice (GCP) for Drug Clinical Trials.

Objectives of the Revision

The updated guidelines were issued under Announcement No. 50 of 2026 and are intended to:

• Optimize quality management for drug clinical trials.
• Support the development of a more standardized clinical research environment.
• Improve the efficiency of clinical research and development activities.
• Promote innovation in biopharmaceutical research and development.

New GCP Guidelines to Take Effect in September 2026

According to the announcement, the revised Good Clinical Practice guidelines will come into force on 1 September 2026.

At the same time, the previous Announcement on Issuing the Good Clinical Practice for Drug Clinical Trials (No. 57 of 2020), jointly issued by the National Medical Products Administration and the National Health Commission, will be repealed.

Supporting Documents Published

The announcement was accompanied by two documents:

1. Good Clinical Practice for Drug Clinical Trials (2026 Revision)
2. Q&A Document on Good Clinical Practice for Drug Clinical Trials (2026 Revision)

These documents provide the revised framework and supporting explanations related to the updated GCP requirements.

Supporting Clinical Trial Compliance

As clinical trial regulations continue to evolve globally, sponsors, CROs, and research organizations must ensure that their clinical development programs remain aligned with current regulatory expectations. Baupharma’s Clinical Research services support organizations throughout the clinical trial lifecycle, helping maintain quality, compliance, and operational efficiency across clinical development activities.

For More Information

Official announcement: Announcement No. 50 of 2026 by the National Medical Products Administration, the National Health Commission, the State Administration of Traditional Chinese Medicine, and the National Bureau of Disease Control and Prevention regarding the issuance of Good Clinical Practice (GCP) guidelines.